Table 3C.

Laboratory findings in 23 patients with reported MAS for LDH.

Group	Patient No.	Event No.	LDH, IU/l				Outcome of MAS
Group	Patient No.	Event No.	Baseline Value	At Time of MAS Onset	Worst Value During MAS	At Time of Outcome	Outcome of MAS
1	1	1	364	572	572	—	Recovered
	2^a	2	—	842	2161	339^e	Recovered
	3	3	—	—	—	—	Recovered
2	3	4	—	599	880	178	Recovered
	4	5	—	544	600	334	Recovered
	5	6	—	1149	1373	325	Recovered
		7	—	667	990	316^e	Recovered
	6	8	—	334	420	235	Recovered
	7	9	—	—	1057	623^e	Recovered
	8	10	—	808	808	520	Recovered
	9^b	11	—	395	785	298	Recovered
	10	12	222	248	950	—	Recovered
	11	13	—	516	516	—	Recovered
	12	14	384	529	529	258	Recovered
	13	15	443	661	26,741	26,741	Not recovered
3	14	16	224	1800^d	2461	499	Recovered
3	15^c	17	—	565^d	1123	528	Improved
Median			364.0	572.0	915.0	334.0
Range			222–443	248–1800	420–26,741	178–26,741
4	16	18	—	472^d	472	368	Recovered
	17	19	—	486	588	289^e	Not recovered
	18	20	—	823^d	882	259^e	Improved
	19	21	—	147	194	130	Recovered
	20	22	—	357	386	274	Recovered
	21	23	543	1107	1206	—	Unknown
	22	24	—	—	—	—	Recovered
	23	25	—	—	—	—	Unknown

Baseline value: Value at start of TCZ administration in the all-patient registry surveillance.
↵a, b, c Representative examples of Group 1 (definitive MAS), Group 2 (probable MAS), and Group 3 (EB-VAHS), respectively.
↵d ± 1 day from onset.
↵e ± 3 days from outcome. Significant values for all 3 tables are in bold face. MAS: macrophage activation syndrome; PLT: platelet; TCZ: tocilizumab; EB-VAHS: Epstein-Barr virus–associated hemophagocytic syndrome; LDH: lactate dehydrogenase.